NEW YORK, NY / ACCESSWIRE / September 13, 2018 / Bausch Health Companies together with Salix's licensors Cedars-Sinai Medical Center and Alfasigma SpA resolve the outstanding intellectual property litigation with Actavis Laboratories. Vital Therapies’ shares dived deep in red following announcement to cease any further development of the ELAD System.
RDI Initiates Coverage on:
Bausch Health Companies Inc.
https://www.rdinvesting.com/report/?ticker=BHC
Vital Therapies, Inc.
https://www.rdinvesting.com/report/?ticker=VTL
Bausch Health Companies Inc. shares hiked 13.88 percent on Wednesday as the company together with Salix's licensors Cedars-Sinai Medical Center and Alfasigma SpA, teamed up to resolve the outstanding intellectual property litigation with Actavis Laboratories FL, Inc., regarding XIFAXAN® (
Access RDI’s Bausch Health Companies Inc. Research Report at:
https://www.rdinvesting.com/report/?ticker=BHC
Shares of Vital Therapies, Inc. plunged 92.86 percent to settle at $0.45 a share after it announces that VTL-308 fail to achieve primary and secondary Endpoints of improvement in survival. While there was an improvement in survival in the ELAD-treated group between three months and one year following randomization, the VTL-308 study failed to reach the primary endpoint of a significant improvement in overall survival through at least 91 days assessed using the Kaplan Meier statistical method. Due to failure, the Company does not believe the ELAD System can be approved in the United States or European Union, if ever, without additional clinical trials which would require substantial capital and time to complete. The Company decided to cease any further development of the ELAD System and explore strategic options. “Although we did not achieve the outcome we were hoping for, we would like to thank those who made this trial possible, including our investigators and their staffs, the patients who were enrolled and their families, and all Vital Therapies employees,” said Russell J. Cox, CEO at Vital Therapies, Inc.
Access RDI’s Vital Therapies, Inc. Research Report at:
https://www.rdinvesting.com/report/?ticker=VTL
Our Actionable Research on Bausch Health Companies Inc. (NYSE: BHC) and Vital Therapies, Inc. (NASDAQ: VTL) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
https://www.accesswire.com/511901/Todays-Research-Reports-on-Stocks-to-Watch-Bausch-Health-Companies-and-Vital-Therapies